Estrogen Improves Insulin Sensitivity and Prediabetes Prevention
Research suggests that estrogen improves metabolic flexibility and may play a protective role against insulin resistance in postmenopausal women. Insulin resistance, a condition where the body’s cells become less responsive to insulin, is a concern for menopausal women due to declining estrogen levels. It can precede prediabetes, type 2 diabetes, and other metabolic disorders. Estrogen helps mitigate insulin resistance by enhancing glucose uptake, improving insulin signaling, reducing unhealthy fat storage (especially visceral fat), and providing anti-inflammatory effects.
Estrogen Improves Insulin Resistance: MHT Shows Significant Benefits in Postmenopausal Women
Menopause hormone therapy (MHT) can significantly reduce insulin resistance in healthy postmenopausal women, according to a meta-analysis conducted between 1998 and 2024. This study found that both estrogen-alone and estrogen-plus-progestogen MHT, administered orally or transdermally, significantly reduced insulin resistance. The estrogen-alone therapy was more effective when compared to combination therapy. Estrogen improves the body’s insulin sensitivity by enhancing glucose uptake and supporting more stable blood sugar regulation.
Estrogen Improves Metabolic Function—but Effects Vary by Form and Context
The relationship between MHT and insulin resistance is complex. Factors such as the route and dosage of estrogen administration, duration of use, and individual health factors influence the effects of MHT. In contrast to MHT prescribed for menopause symptoms, hormonal birth control containing estrogen and progestin can make blood sugar management more difficult in women with prediabetes or diabetes. MHT is not currently approved or recommended solely for the prevention of type 2 diabetes. The decision to use MHT should involve consultation with a healthcare professional to assess individual risks and benefits.
